clinical trial · NCT06116110
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Miltenyi Biomedicine GmbH·—·recruiting·n = 150
Non Hodgkin LymphomaLong-term Follow-Up
brief summary
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
started
May 15, 2024
primary completion
Dec 1, 2039
completion
Dec 1, 2039
last updated
Nov 20, 2024
detailed description
This is a non-therapeutic study design. After successful screening, subjects will be monitored for potential gene therapy-related adverse events for up to 15 years post MB-CART2019.1 infusion. Subjects will be assessed yearly for the occurrence of delayed adverse events (AEs), monitored for replication competent lentivirus (RCL) and assessed for long term efficacy as well as CAR-T persistence.
official title
A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a United States Miltenyi Biomedicine-Sponsored Clinical Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol